Bain Capital Life Sciences
Bain Capital Life Sciences, founded in 2016, leverages Bain Capital's extensive history in healthcare and life sciences investing. The firm focuses on investing in biopharmaceutical, medical device, diagnostic, and life science tool companies globally, aiming to drive medical innovation and improve the lives of patients with unmet medical needs. With a team of over 25 professionals, Bain Capital Life Sciences provides strategic support to clinical and commercial-stage companies, facilitating critical phases of value creation.
Bain Capital Life Sciences
200 Clarendon Street, Boston, MA 02116, United States
Portfolio
#Biotechnology
#Biotechnology
#Biotechnology
#Biotechnology
#Biotechnology
#Biotechnology
#Biotechnology
#Biotechnology
#Biotechnology
#Biotechnology
#Biotechnology
#Biotechnology
#Biotechnology
#Biotechnology
#Biotechnology
#Biotechnology
#Biotechnology
#Biotechnology
#Biotechnology
#Biotechnology
#Biotechnology
Kailera Therapeutics is developing a broad, advanced, and differentiated portfolio of clinical-stage injectable and oral therapies for the treatment of obesity and related conditions. Kailera’s most advanced program, KAI-9531, is an injectable GLP-1/GIP receptor dual agonist that has demonstrated positive results in Phase 2 trials in obesity and type 2 diabetes in China.
#Biotechnology
#Biotechnology
#Biotechnology
#Biotechnology
#Biotechnology
#Biotechnology
#Biotechnology
#Biotechnology
#Biotechnology
#Biotechnology
#Biotechnology
#Biotechnology
#Biotechnology
#Biotechnology
#Biotechnology
#Biotechnology
#Biotechnology
#Biotechnology
#Biotechnology
Key People
Associate
Managing Director
Principal
Associate
Vice President
Vice President